Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Zeria’s Hyperkalemia Drug Veltassa Now Available in Japan
March 17, 2025
- Jiho Survey Finds Improvement in Price Revision Rates for Generic Players
March 17, 2025
- KalVista Eyes Japan Debut with World’s 1st Oral On-Demand HAE Drug
March 14, 2025
- FDA Rejects Seikagaku’s Herniated Disk Drug
March 14, 2025
- Glaucoma Eye Drop Rocklatan Now Available in Singapore: Santen
March 14, 2025
- Pfizer Japan Files NDA for Tucatinib for HER2 Breast Cancer
March 14, 2025
- Mitsubishi Tanabe’s Oral Edaravone Filed in South Korea
March 14, 2025
- Biogen Japan to Launch ALS Drug Qalsody upon Listing on March 19
March 14, 2025
- Rxulti Expands Label into Schizophrenia in Adolescents in Europe
March 14, 2025
- Ono Licenses in Polycythemia Vera Drug Candidate from Ionis
March 13, 2025
- More than Half of Drug Makers’ Top 5 Meds See Flat or Positive Revisions: Poll
March 12, 2025
- Two-Thirds of Drug Makers Discontent with FY2025 Price Revision: Survey
March 11, 2025
- Chugai CEO Vows to Cherish Employees at 100th Anniversary
March 11, 2025
- Kyowa Kirin/Amgen’s Eczema Drug Hits Main Goal in Global PIII
March 11, 2025
- Drug Makers Weigh Withdrawal of Unprofitable Drugs, Generic and Innovative Players Alike: Poll
March 11, 2025
- Daiichi Curbs Enhertu Shipments on Spiking Demand in Japan
March 11, 2025
- Amitiza Notches Triple Crowns in Hospital Doctor Promotion in January: Intage
March 11, 2025
- Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
March 10, 2025
- Astellas, Yaskawa Electric to Form JV for Cell Therapy Production
March 10, 2025
- Sandoz’s Rituxan Biosimilar Adds Nephrotic Syndrome Use
March 10, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…